Calidi Biotherapeutics, Inc.

Snapshot

Calidi is a clinical-stage biotech with no revenue and a $19.9M net loss in FY 2025. Cash sits at just $4.1M against $1.9M of debt, and Signal8 models roughly half a month of runway.

What's Happening Right Now

• Mon 19th Oct '26 · Conference presentation: Calidi will present new preclinical data on CLD-401 and its In Situ T-cell engager programs at ESMO Congress 2026 in Madrid, Oct 23-27, 2026; CLD-401 remains in IND-enabling studies.
• Fri 25th Sep '26 · Listing notice: On Sep 21, 2026, NYSE American notified Calidi it fails stockholders' equity listing standards, with no exemption available; the company must submit a compliance plan by Oct 21, 2026 or face delisting.
• Tue 22nd Sep '26 · Equity raise: Calidi closed a $1.2 million registered direct offering on Sep 21, 2026, selling shares at $1.17 each, with a 45-day standstill on new equity issuances and 60-day officer lock-ups.
• Mon 21st Sep '26 · Offering: Raised $1.20M in gross proceeds through a registered direct offering.
• Thu 13th Aug '26 · Going concern: Calidi's 10-Q for the quarter ended Jun 30, 2026 disclosed substantial doubt about continuing as a going concern, $4.1 million cash against $8.5 million of first-half burn, a $149.9 million accumulated deficit, and a completed 1-for-16 reverse split.
• Thu 13th Aug '26 · FDA feedback: Calidi received positive pre-IND feedback from the FDA for CLD-401, targeting first patient dosing in Q1 2027, alongside a Q2 2026 net loss of $4.2 million and $4.3 million in cash.
• Mon 10th Aug '26 · ATM sale: Sold $900K net / 491K shares through its at-the-market program, as stated for Jul 1, 2026 to Aug 10, 2026.
• Tue 30th Jun '26 · ATM sale: Sold $2.30M of stock / 876K shares through its at-the-market program, as stated for Jan 1, 2026 to Jun 30, 2026.